Abstract
Edwards Lifesciences will report its second-quarter 2026 financial results on July 23, 2026 Post-Mkt, with investors expecting double‑digit revenue and adjusted EPS growth as procedure momentum, policy developments, and new product catalysts shape the setup for the print.Market Forecast
For the current quarter, market expectations point to revenue of 1.70 billion US dollars, an increase of 14.19% year over year, adjusted EPS of 0.74 (up 18.99% year over year), and EBIT of 478.99 million US dollars (up 17.60% year over year). Forecasts for gross profit margin and net margin are not disclosed in the available estimates. The core product lines are expected to remain the main growth engines, with transcatheter heart valve therapies supported by procedure growth and policy tailwinds; the most promising near-term opportunity is transcatheter aortic valve replacement, where last quarter’s segment revenue reached 1.37 billion US dollars, and physician checks suggest national procedure volumes could rise about 5% year over year under updated coverage parameters.Last Quarter Review
In the prior quarter, Edwards Lifesciences delivered revenue of 1.65 billion US dollars (up 16.70% year over year), a gross profit margin of 78.01%, GAAP net profit attributable to the parent of 381.00 million US dollars, a net profit margin of 23.09%, and adjusted EPS of 0.78 (up 21.88% year over year). A notable highlight was profitability: GAAP net profit rose sharply on a sequential basis, with quarter‑on‑quarter growth of 317.43%, and management raised the full‑year adjusted EPS outlook to a new range centered around 2.95 to 3.05 US dollars, signaling confidence in execution and demand resilience. Main business performance remained concentrated in structural heart therapies, with transcatheter heart valve therapies contributing 1.37 billion US dollars (approximately 83.25% of total revenue) and surgical heart valve therapies contributing 276.20 million US dollars (about 16.75%), while company‑level revenue grew 16.70% year over year.Current Quarter Outlook
Transcatheter Heart Valve Therapy
Transcatheter platforms remain the company’s most consequential driver this quarter, anchored by expected procedure growth in aortic valve replacement. The forecasted 14.19% revenue increase lines up with the expectation that utilization is holding firm and that referral funnels continue to normalize, with throughput at centers improving compared with last year. Within the United States, physician commentary indicates that coverage and operational adjustments could add roughly 5% to national transcatheter aortic valve procedure volumes, a support that may not be fully captured by headline quarterly models but offers a constructive directional cue for the back half of the year. Outside the US, stable expansion in selected high‑growth markets remains a secondary support, though quarterly variability in tenders and hospital purchasing cycles can affect timing.Pricing and mix will be watched closely. While list pricing in core valves tends to be disciplined, mix shifts toward newer‑generation systems and complex cases can modestly influence average selling prices and gross margin. Investors will track whether gross profit margin holds near the 78.01% prior‑quarter baseline; a flat to slightly higher trajectory would signal healthy manufacturing yields and disciplined discounting, whereas any meaningful contraction could imply elevated competition or higher input costs. Reinvestment in clinical programs remains part of the story: continued enrollment and data development in trials related to disease severity cohorts are key to expanding the treated population in the medium term, but quarterly P&L effects will arrive mainly through operating expense cadence rather than revenue spikes.
Looking through the quarter, catalysts in procedure workflow—such as the ongoing normalization of staffing and operating room capacity—should support steady case growth, though the magnitude can vary by center and region. On balance, a mid‑teens revenue growth print for the company, if achieved, would be consistent with stable demand in transcatheter aortic valve replacement. Any commentary on share dynamics, conversion rates among moderate‑severity patients, or centers adopting updated site and staffing models could shape expectations for the second half of the year.
Structural Heart Repair and the Pascal Platform
The transcatheter repair franchise for mitral and tricuspid disease continues to be an important area for incremental growth. Clinical adoption trends, especially in complex mitral regurgitation cases, remain a focal point for this quarter’s call. Analysts tracking procedure volumes expect gradual expansion driven by technology enhancements and growing operator familiarity, rather than abrupt, quarter‑to‑quarter changes. The company’s discussions at recent medical meetings included additional data disclosures that build physician confidence on safety and efficacy endpoints, which can help sustain utilization growth as centers expand therapy lines for appropriate patients.Beyond valve replacement and repair, Edwards Lifesciences recently received US clearance for a left atrial appendage exclusion system, adding a new adjacency that complements its cardiac structural portfolio over time. While revenue contributions from this system should be modest at launch, the clearance is additive to the product cadence and provides optionality for longer‑term growth. Integration with advanced imaging and workflow solutions is a further watch item: more precise guidance during complex structural procedures can reduce procedural time and complication rates, potentially improving hospital economics—an important lever for adoption.
Investors should also monitor ongoing intellectual property litigation in the repair space. While the matter remains at an early stage and quarterly financial impact is not anticipated in the near term, legal developments can influence sentiment around the repair franchise’s longer‑term growth trajectory. Management’s commentary on case mix, site additions, training pipelines, and any updates to product enhancements will be closely parsed for implications to 2026–2027 growth algorithms. In the near term, the repair portfolio’s contribution is expected to be an incremental tailwind, complementing the core replacement business.
Key Stock Price Drivers This Quarter
The stock’s near‑term reaction is likely to hinge on four elements: revenue versus the 1.70 billion US dollars benchmark, margin trajectory versus the 78.01% baseline, the tone of full‑year guidance, and visibility on policy and product catalysts for the back half. A revenue outcome at or above the consensus estimate, especially if accompanied by resilient gross margin and operating discipline, would support the narrative of balanced growth across replacement and repair. On the other hand, any shortfall versus the top‑line estimate could tighten the permissible range for full‑year guidance and elevate scrutiny on the pace of procedure growth in core transcatheter aortic valve indications.Gross margin is a swing factor for sentiment. The prior quarter’s 78.01% level sets a high bar; investors will look for stability or modest improvement, indicating continued manufacturing efficiencies and healthy mix. Operating expenses may trend higher as the company invests behind clinical programs, commercial launches, and training; even so, EBIT of 478.99 million US dollars is expected, implying leverage if revenue meets or beats expectations. Should management reiterate or lift full‑year adjusted EPS guidance from its recently raised range, the market may gain confidence in above‑trend earnings momentum into year‑end.
Policy developments and coverage criteria remain a critical underpinning for procedure volume growth over the medium term. Analyst checks point to coverage adjustments that could improve procedural efficiency and expand eligible patient cohorts. Commentary on how centers are implementing staffing and site changes will inform the pace of quarterly adoption. Separately, the CFO transition completed in late spring is not expected to change capital allocation priorities; nevertheless, investors will pay attention to any updates on M&A appetite in light of recent regulatory scrutiny around consolidation in specialized therapy areas.
Product cadence is the other swing factor. The recent left atrial appendage exclusion clearance adds a complementary device line, but its immediate revenue impact should be incremental. In contrast, ongoing enhancements to transcatheter repair systems and expanded indications in replacement could meaningfully shift 2027 and beyond expectations. Finally, while the intellectual property landscape bears watching, it is not expected to alter the near‑term revenue trajectory; any disclosures on legal timelines or potential contingencies will be assessed in the context of cash flow and guidance.
Analyst Opinions
Among the institutional notes collected since January 1, 2026, the balance of opinion is decisively positive: the overwhelming majority are Buy/Outperform, with virtually no bearish calls, reflecting a clear bullish skew ahead of the quarter. Citi reiterated a Buy with a 110 US dollars target, citing confidence in the trajectory of transcatheter procedures and the potential for sustained double‑digit earnings growth supported by operating leverage. BTIG maintained Buy and lifted its target to 110 US dollars, highlighting the combination of procedure momentum and product catalysts that can extend mid‑teens revenue growth beyond the near term. Mizuho kept an Outperform and raised its target to 105 US dollars, pointing to favorable policy updates for aortic valve procedures and consistent execution through the first half. Evercore ISI raised its target to 100 US dollars and remained constructive on the durability of growth drivers into 2027. Redburn affirmed Buy with a 99 US dollars target, emphasizing a balanced setup across replacement and repair with potential upside from new therapy adjacencies. Barclays maintained Buy at 104 US dollars, underscoring supportive demand indicators and a robust second‑half pipeline of clinical milestones. Wolfe Research upgraded to Buy with a 92 US dollars target, citing an attractive risk‑reward as growth visibility improves. A neutral stance from one broker at 87 US dollars represents the minority view and does not shift the prevailing positive consensus.The bullish case coalesces around three pillars. First, demand support: checks suggest a constructive environment for transcatheter aortic valve procedures, with coverage adjustments likely to make more efficient use of operating resources and extend access to appropriate patients, which could translate into a 5% uplift in national procedure volumes over time. Second, margin and earnings quality: analysts expect a continuation of high gross margins near the prior quarter’s 78.01% level, with incremental operating leverage as revenue scales and investments are absorbed, which underpins the 18.99% year‑over‑year increase in adjusted EPS embedded in this quarter’s forecasts. Third, catalysts and optionality: the clearance of the left atrial appendage exclusion system offers a new adjacency, while ongoing repair enhancements and clinical data readouts offer medium‑term levers that are not fully reflected in near‑term estimates.
In dissecting potential surprises, bullish analysts see upside risk to the top line if procedure growth outpaces current assumptions in select geographies or if mix favors higher‑value systems. They also point to the possibility that management maintains or nudges up full‑year adjusted EPS guidance given the raised range announced last quarter and solid first‑half execution. On the flip side, the same analysts acknowledge that quarterly volatility in hospital purchasing, foreign‑exchange effects, and legal overhangs can add noise to the P&L, but they view these as manageable within the current guidance framework. Overall, the majority view anticipates a clean result around or above the 1.70 billion US dollars revenue and 0.74 adjusted EPS markers, supported by steady procedure growth and disciplined cost control, and looks for commentary that affirms policy tailwinds and a well‑sequenced product cadence into year‑end and 2027.
Comments